PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline-and taxane-based chemotherapy: Correlative analysis of C9741 (alliance)

npj Breast Cancer

Volumn 2, Issue 1, 2016, Pages

  Liu, Minetta C ^a   Pitcher, Brandelyn N ^b   Mardis, Elaine R ^c   Davies, Sherri R ^c   Friedman, Paula N ^d   Snider, Jacqueline E ^c   Vickery, Tammi L ^c   Reed, Jerry P ^c   Deschryver, Katherine ^e   Singh, Baljit ^f   Gradishar, William J ^g   Perez, Edith A ^h   Martino, Silvana ⁱ   Citron, Marc L ^j   Norton, Larry ^k   Winer, Eric P ^l   Hudis, Clifford A ^k   Carey, Lisa A ^m   Bernard, Philip S ⁿ   Nielsen, Torsten O ^o   Perou, Charles M ^m   Ellis, Matthew J ^p   Barry, William T ^q   more..

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p USA   (United States)

^q DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85047066317     PISSN: None     EISSN: 23744677     Source Type: Journal    
DOI: 10.1038/npjbcancer.2015.23     Document Type: Article

References (29)

1. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
2. Prat, A., Ellis, M. J. & Perou, C. M. Practical implications of gene-expression-based assays for breast oncologists. Nat. Rev. Clin. Oncol. 9, 48–57 (2012).
3. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
4. Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5, 5–23 (2011).
5. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
6. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
7. Nielsen, T. O. et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 5222–5232 (2010).
8. Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439 (2003).
9. Berry, D. A. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295, 1658–1667 (2006).
10. Jatoi, I. et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J. Clin. Oncol. 29, 2301–2304 (2011).
11. Bianchini, G. et al. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res. 15, R86 (2013).
12. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
13. van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
14. Sotiriou, C. et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262–272 (2006).
15. Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607–616 (2004).
16. Martin, M. et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res. Treat. 138, 457–466 (2013).
17. Norton, L. A Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067–7071 (1988).
18. Cheang, M. C. et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin. Cancer Res. 18, 2402–2412 (2012).
19. Esserman, L. J. et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat. 132, 1049–1062 (2012).
20. Hudis, C. A. et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 25, 2127–2132 (2007).
21. McShane, L. M. et al. Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23, 9067–9072 (2005).
22. Dowsett, M. et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 31, 2783–2790 (2013).
23. Thor, A. D. et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl Cancer Inst. 90, 1346–1360 (1998).
24. Hayes, D. F. et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357, 1496–1506 (2007).
25. Rimm D. L. et al. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J. Clin. Oncol. 2011; 29: 2282–2290.
26. Cheang, M. C. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl Cancer Inst. 101, 736–750 (2009).
27. Cheang, M. C. et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14, 1368–1376 (2008).
28. Harrell F. E. Regression modeling strategies: R package version 3.6-3. http://CRAN.R-project.org/package = rms (2013).
29. R Development Core Team. R: A Language and Environment for Statistical Computing. The R Foundation for Statistical Computing: Vienna, Austria (2012).